Immunome annual depreciation and amortization
2019
2020
2021
2022
2023
2024
2025
Immunome Depreciation & Amortization Growth & History (IMNM)
Immunome's depreciation and amortization was $2.5M for fiscal 2025.
View full Immunome company overviewImmunome annual depreciation and amortization history
| Fiscal year | Period ended | Depreciation and amortization | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.5M | $899,000 | +57.37% |
| 2024 | 2024-12-31 | $1.6M | $1.1M | +242.89% |
| 2023 | 2023-12-31 | $457,000 | $35,000 | +8.29% |
| 2022 | 2022-12-31 | $422,000 | −$333,000 | −44.11% |
| 2021 | 2021-12-31 | $755,000 | $0 | 0.00% |
| 2020 | 2020-12-31 | $755,000 | $140,000 | +22.76% |
| 2019 | 2019-12-31 | $615,000 | — | — |
Immunome quarterly depreciation and amortization
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Depreciation and amortization | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $957,000 | $320,000 | +50.24% |
| Q1 2026 | 2026-03-31 | $603,000 | −$8,000 | −1.31% |
| Q4 2025 | 2025-12-31 | $776,000 | — | — |
| Q3 2025 | 2025-09-30 | $589,000 | $178,000 | +43.31% |
| Q2 2025 | 2025-06-30 | $637,000 | $88,000 | +16.03% |
| Q1 2025 | 2025-03-31 | $611,000 | $454,000 | +289.17% |
| Q3 2024 | 2024-09-30 | $411,000 | $300,000 | +270.27% |
| Q2 2024 | 2024-06-30 | $549,000 | $448,000 | +443.56% |
| Q1 2024 | 2024-03-31 | $157,000 | $63,000 | +67.02% |
| Q3 2023 | 2023-09-30 | $111,000 | $8,000 | +7.77% |
| Q2 2023 | 2023-06-30 | $101,000 | −$12,000 | −10.62% |
| Q1 2023 | 2023-03-31 | $94,000 | −$17,000 | −15.32% |
| Q3 2022 | 2022-09-30 | $103,000 | −$183,000 | −63.99% |
| Q2 2022 | 2022-06-30 | $113,000 | −$62,000 | −35.43% |
| Q1 2022 | 2022-03-31 | $111,000 | −$65,000 | −36.93% |
| Q3 2021 | 2021-09-30 | $286,000 | $109,000 | +61.58% |
| Q2 2021 | 2021-06-30 | $175,000 | $16,000 | +10.06% |
| Q1 2021 | 2021-03-31 | $176,000 | $13,000 | +7.98% |
| Q3 2020 | 2020-09-30 | $177,000 | — | — |
| Q2 2020 | 2020-06-30 | $159,000 | — | — |
| Q1 2020 | 2020-03-31 | $163,000 | — | — |
Immunome depreciation and amortization trends
Over the last five fiscal years, Immunome's depreciation and amortization increased from $755,000 to $2.5M, a change of $1.7M. The latest reported quarter, Q2 2026, shows $957,000.
About the metric
What depreciation and amortization mean
Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.
Calculation and source
Reported depreciation and amortization
TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Immunome source filings ↗